D. J. Sargent

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

M Buyse, D. Sargent, M. Buyse, 2011, European journal of cancer.

Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume.

D. Sargent, R. Coffey, R. Kline, 1999, International journal of radiation oncology, biology, physics.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

T. Smyrk, S. Alberts, M. Mahoney, 2013 .